E6 UBE3A TP53 Aberrant proliferation E7 RB1/E2F CUL2 Figure 6. Therapeutic Targeting of the Hallmarks of Cancer Drugs that interfere with each of the acquired capabilities necessary for tumor growth and progression have been developed and are in clinical trials o cases approved for clinical use in treating certain forms of human cancer. Additionally, the investigational drugs are being developed to target ea E5 ? E5 E7 E7 E7 E7 E7 E7 E6 E6 E6 E6 E6 E6 E7 E6 E6 Hanahan & Weinberg Cell 144: 646-‐74, 2011 Mesri, Feitelson & Munger Cell Host &Microbes 15: 266-‐82, 2014 High-‐risk alpha HPV carcinogenesis